Abstract
The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria. Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development. In this light, we also summarize recent progress made in the development of inhibitors of sulfur metabolism enzymes.
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design and inhibitors.
Infectious Disorders - Drug Targets
Title:New Targets and Inhibitors of Mycobacterial Sulfur Metabolism
Volume: 13 Issue: 2
Author(s): Hanumantharao Paritala and Kate S. Carroll
Affiliation:
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design and inhibitors.
Abstract: The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria. Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development. In this light, we also summarize recent progress made in the development of inhibitors of sulfur metabolism enzymes.
Export Options
About this article
Cite this article as:
Paritala Hanumantharao and Carroll S. Kate, New Targets and Inhibitors of Mycobacterial Sulfur Metabolism, Infectious Disorders - Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/18715265113139990022
DOI https://dx.doi.org/10.2174/18715265113139990022 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Mechanism of Bioactive Transfer through Liposomal Bilayers
Current Drug Targets An Experience with Delamanid in an XDR TB Case – Case Report
Infectious Disorders - Drug Targets Large-Scale Prediction of Protein Structure and Function from Sequence
Current Pharmaceutical Design MIANN Models of Networks of Biochemical Reactions, Ecosystems, and U.S. Supreme Court with Balaban-Markov Indices
Current Bioinformatics Insights in Nanoparticle-Bacterium Interactions: New Frontiers to Bypass Bacterial Resistance to Antibiotics
Current Pharmaceutical Design Isoprenoid Biosynthesis of the Apicoplast as Drug Target
Current Drug Targets The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Fluoroquinolones as Chemotherapeutics Against Mycobacterial Infections
Current Pharmaceutical Design Enhanced Efficacy of DNA Vaccines Against an Intracellular Bacterial Pathogen by Genetic Adjuvants
Current Pharmaceutical Biotechnology Life Threatening and Fatal Contrast Media Reactions: Pathomechanisms, Diagnosis, Prevention and Drug Management
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases
Current Pharmaceutical Design Microwave-Assisted Multicomponent Reactions: Rapid and Regioselective Formation of New Extended Angular Fused Aza-Heterocycles
Combinatorial Chemistry & High Throughput Screening Novel Dibenzothiepins with Antibiofilm Activity Demonstrated by Microbiological Assays and Molecular Modeling
Current Organic Chemistry Bactericidal and Hemolytic Activities of Synthetic Peptides Derived from Granulysin
Protein & Peptide Letters The Contribution of Host Genetics to TB Disease
Current Respiratory Medicine Reviews An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis
Current Medicinal Chemistry A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications
Current Drug Metabolism Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Centrality Measures in Biological Networks
Current Bioinformatics